Omnix Medical Granted Fast-Track Designation by U.S. FDA for its Next-Generation Anti-Infective OMN6
20 févr. 2024 04h00 HE
|
AKAMPION
- Designation underlines the need for novel, first-in-class antimicrobials for the treatment of infections with Gram-negative bacteria JERUSALEM, Israel, February 20, 2023 -- Omnix Medical, a...
Omnix Medical Receives U.S. FDA Approval of a Phase II Trial of its Next-Generation Anti-Infective OMN6
20 nov. 2023 04h00 HE
|
AKAMPION
- Phase I data show safety and tolerability at clinically significant dose levels- New class of anti-infectives to treat infections with Gram-negative bacteria JERUSALEM, Israel, November 20,...
Animal Drug Compounding Market is Predicted to Reach USD 2.4 billion by 2031, Registering a 7.4% CAGR: TMR Report
04 oct. 2023 03h47 HE
|
Transparency Market Research
Wilmington, Delaware, United States, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The animal drug compounding market acquired US$ 1.1 billion in 2021. The market is likely...
AUROBAC THERAPEUTICS welcomes two new independent members to its Board: Manos Perros, as Chairman, and Marco Taglietti
24 juil. 2023 08h00 HE
|
AUROBAC THERAPEUTICS
Lyon - France, July 24, 2023 (GLOBE NEWSWIRE) -- AUROBAC THERAPEUTICS WELCOMES TWO NEW INDEPENDENT MEMBERS TO ITS BOARD: MANOS PERROS, AS CHAIRMAN, AND MARCO TAGLIETTI Dr Manos Perros and Dr...
Aridis Receives Agreement from the FDA on a Single Confirmatory Phase 3 Study of AR-301 and the Clinical Study Design
31 mai 2023 08h00 HE
|
Aridis Pharmaceuticals, Inc.
LOS GATOS, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced positive feedback from the FDA on the Company’s proposed single confirmatory Phase 3...
Omnix Medical Announces Excellent Topline Data from the Phase I Clinical Trial of its Novel Anti-Infective OMN6
08 mai 2023 03h30 HE
|
AKAMPION
- OMN6 demonstrates safety and tolerability at clinically significant dose levels JERUSALEM, Israel, May 8th, 2023 -- Omnix Medical, a biopharmaceutical company developing next-generation...
Aridis Reports Top-Line Results of the Phase 3 Double-Blinded, Superiority Trial of AR-301 For the Treatment of Staphylococcus aureus Ventilator Associated Pneumonia (VAP)
25 janv. 2023 16h05 HE
|
Aridis Pharmaceuticals, Inc.
LOS GATOS, Calif, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced top-line results from the AR-301-002 Phase 3 study, which evaluated the superiority of...
Animal Healthcare Market to hit USD 238 Billion by 2032, says Global Market Insights Inc.
11 janv. 2023 07h10 HE
|
Global Market Insights Inc.
Selbyville, Delaware, Jan. 11, 2023 (GLOBE NEWSWIRE) -- The animal healthcare market value is set to reach USD 238 billion by 2032, according to a new research report by Global Market Insights...
Companion Animal Drugs Market to hit USD 24.5 billion by 2032, says Global Market Insights Inc.
05 déc. 2022 07h10 HE
|
Global Market Insights Inc.
Selbyville, Delaware, Dec. 05, 2022 (GLOBE NEWSWIRE) -- The companion animal drugs market value is estimated to gains USD 24.5 billion by 2032, as per a new research report by Global Market...
Europe Animal Healthcare Market revenue to surpass $49.4bn by 2027, says Graphical Research
26 avr. 2022 03h12 HE
|
Graphical Research
Pune, India, April 26, 2022 (GLOBE NEWSWIRE) -- As per a recent industry report put forward by Graphical Research, the Europe animal healthcare market is forecast to register its name in the...